rituximab,CC-95251
roche,biogen,BMS
['cart,(-cartitude)', 'nhl', 'lymsm', 'rituximab', 'lymphoma']
congress #eha2022 | paolo strati, , presents the results with cc-95251, an anti-sirp antibody, in combination with rituximab, in heavily pretreated patients with cd20+ nhl. of note, patients with previous sct or #cartcell were eligible #lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm